FDA Lays Out New Approaches for Trials of Fatty Liver Drugs

Drug Industry Daily
A A
Drug sponsors should break down nonalcoholic fatty liver disease into three stages and focus on the most dangerous, the FDA suggests in new draft guidance issued Monday.

To View This Article:

Login

Subscribe To Drug Industry Daily